# Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

> **NCT00295932** · PHASE1,PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 79 (actual)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** bortezomib
- **DRUG:** cyclophosphamide
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT00295932
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12-13
- **Primary completion:** 2018-03-11
- **Final completion:** 2018-03-11
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2018-11-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00295932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00295932, "Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00295932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*